Robert E. Hawkins

16.3k total citations · 4 hit papers
166 papers, 12.3k citations indexed

About

Robert E. Hawkins is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Robert E. Hawkins has authored 166 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Oncology, 64 papers in Immunology and 59 papers in Molecular Biology. Recurrent topics in Robert E. Hawkins's work include CAR-T cell therapy research (58 papers), Immunotherapy and Immune Responses (44 papers) and Renal cell carcinoma treatment (34 papers). Robert E. Hawkins is often cited by papers focused on CAR-T cell therapy research (58 papers), Immunotherapy and Immune Responses (44 papers) and Renal cell carcinoma treatment (34 papers). Robert E. Hawkins collaborates with scholars based in United Kingdom, United States and Germany. Robert E. Hawkins's co-authors include Greg Winter, David E. Gilham, Andrew D. Griffiths, Hennie R. Hoogenboom, Robin W. Carrell, Christine C. Winterbourn, Stephen J. Russell, Cezary Szczylik, Lauren McCann and Cora N. Sternberg and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Circulation.

In The Last Decade

Robert E. Hawkins

160 papers receiving 11.8k citations

Hit Papers

Pazopanib in Locally Advan... 1975 2026 1992 2009 2010 1994 1975 1992 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
    2010 1.9k citations Cora N. Sternberg, Ian D. Davis et al. Journal of Clinical Oncology profile →
  2. Making Antibodies by Phage Display Technology
    1994 1.2k citations Robert E. Hawkins et al. profile →
  3. The estimation of red cell superoxide dismutase activity.
    1975 937 citations Robert E. Hawkins et al. profile →
  4. Selection of phage antibodies by binding affinity
    1992 404 citations Robert E. Hawkins et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert E. Hawkins United Kingdom 52 5.6k 4.9k 3.2k 2.8k 2.5k 166 12.3k
James D. Griffin United States 95 12.8k 2.3× 7.4k 1.5× 1.9k 0.6× 5.3k 1.9× 1.3k 0.5× 354 29.7k
Kristoffer Valerie United States 60 6.4k 1.1× 3.9k 0.8× 1.2k 0.4× 1.3k 0.5× 911 0.4× 164 10.4k
Glenn Merlino United States 73 10.9k 2.0× 6.1k 1.2× 1.4k 0.4× 2.3k 0.8× 918 0.4× 215 17.9k
Adriana Heguy United States 60 6.9k 1.2× 3.2k 0.7× 2.3k 0.7× 1.9k 0.7× 648 0.3× 178 14.0k
Jan Paul Medema Netherlands 73 11.0k 2.0× 9.7k 2.0× 1.5k 0.5× 5.0k 1.8× 700 0.3× 266 21.8k
Ib Jarle Christensen Denmark 61 5.4k 1.0× 5.6k 1.1× 2.0k 0.6× 2.5k 0.9× 790 0.3× 446 15.3k
Salvatore V. Pizzo United States 71 7.5k 1.3× 2.0k 0.4× 3.0k 0.9× 2.8k 1.0× 894 0.4× 395 17.2k
Barbara Seliger Germany 65 5.3k 1.0× 6.3k 1.3× 1.4k 0.4× 8.1k 2.9× 822 0.3× 362 15.2k
James P. Quigley United States 54 5.5k 1.0× 3.8k 0.8× 810 0.3× 2.0k 0.7× 412 0.2× 119 12.5k
Vassilis G. Gorgoulis Greece 63 11.6k 2.1× 5.4k 1.1× 1.5k 0.5× 2.0k 0.7× 473 0.2× 331 18.5k

Countries citing papers authored by Robert E. Hawkins

Since Specialization
Citations

This map shows the geographic impact of Robert E. Hawkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Hawkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Hawkins more than expected).

Fields of papers citing papers by Robert E. Hawkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Hawkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Hawkins. The network helps show where Robert E. Hawkins may publish in the future.

Co-authorship network of co-authors of Robert E. Hawkins

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Hawkins. A scholar is included among the top collaborators of Robert E. Hawkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Hawkins. Robert E. Hawkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Armstrong, Andrew J., Andrew B. Nixon, Qian Yang, et al.. (2021). Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(12). 3317–3328. 18 indexed citations
3.
Aranson, Nathan J., et al.. (2020). Six-Year Outcomes of the Endologix AFX1 Endovascular AAA System: A Single-Center Experience. Journal of Vascular Surgery. 72(3). e291–e291. 1 indexed citations
4.
Hawkins, Robert E., Martin Gore, Yaroslav Shparyk, et al.. (2016). A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Clinical Cancer Research. 22(13). 3172–3181. 23 indexed citations
5.
Armstrong, Andrew J., Susan Halabi, Tim Eisen, et al.. (2016). Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. The Lancet Oncology. 17(3). 378–388. 311 indexed citations
6.
Gilham, David E., John Anderson, John S. Bridgeman, et al.. (2015). Adoptive T-Cell Therapy for Cancer in the United Kingdom: A Review of Activity for the British Society of Gene and Cell Therapy Annual Meeting 2015. Human Gene Therapy. 26(5). 276–285. 15 indexed citations
7.
Hawkins, Robert E., et al.. (2015). Patient needs in advanced Renal Cell Carcinoma: What are patients’ priorities and how well are we meeting them?. Patient Experience Journal. 2(2). 142–152. 3 indexed citations
8.
Casucci, Monica, Robert E. Hawkins, Gianpietro Dotti, & Attilio Bondanza. (2014). Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunology Immunotherapy. 64(1). 123–130. 48 indexed citations
9.
Hawkins, Robert E.. (2011). CONSTITUTIONAL WORKAROUNDS : SENATE REFORM AND OTHER EXAMPLES. The Canadian Bar Review. 89(3).
10.
Sternberg, Cora N., Ian D. Davis, Jozef Mardiak, et al.. (2010). Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 28(6). 1061–1068. 1940 indexed citations breakdown →
11.
Hawkins, Robert E.. (2010). The Conduct of Public Inquiries: Law, Policy, and Practice. The Canadian Bar Review. 88(3). 3 indexed citations
12.
Cheadle, Eleanor J., et al.. (2010). Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells. The Journal of Immunology. 184(4). 1885–1896. 61 indexed citations
13.
14.
Jiang, Hui‐Rong, et al.. (2006). Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors. The Journal of Immunology. 177(7). 4288–4298. 24 indexed citations
15.
Armstrong, Anne, Eleanor J. Cheadle, & Robert E. Hawkins. (2005). Toward Personalized Immunotherapy for Non-Hodgkin Lymphoma. BioDrugs. 19(5). 289–297. 2 indexed citations
16.
Bhattacharyya, Tapan, Anne Armstrong, Cheng Qian, et al.. (2004). Use of adenoviruses encoding CD40L or IL‐2 against B cell lymphoma. International Journal of Cancer. 111(6). 910–920. 16 indexed citations
17.
Bramhall, Simon R., M T Hallissey, J Whiting, et al.. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. British Journal of Cancer. 86(12). 1864–1870. 199 indexed citations
18.
Dermime, Said, Anne Armstrong, Robert E. Hawkins, & Peter L. Stern. (2002). Cancer vaccines and immunotherapy. British Medical Bulletin. 62(1). 149–162. 51 indexed citations
19.
20.
Hawkins, Robert E., et al.. (1992). Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. Cancer. 69(9). 2271–2275. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James D. Griffin Breakdown of academic impact, for papers by Kristoffer Valerie Breakdown of academic impact, for papers by Glenn Merlino Breakdown of academic impact, for papers by Adriana Heguy Breakdown of academic impact, for papers by Jan Paul Medema Breakdown of academic impact, for papers by Ib Jarle Christensen Breakdown of academic impact, for papers by Salvatore V. Pizzo Breakdown of academic impact, for papers by Barbara Seliger Breakdown of academic impact, for papers by James P. Quigley Breakdown of academic impact, for papers by Vassilis G. Gorgoulis
Rankless by CCL
2026